Oppenheimer Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Oppenheimer Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.43M	Sell	5,346 -1,998	-27%	-$467K	0.01%	668
2026 Q1	$1.68M	Buy	7,344 +1,655	+29%	+$371K	0.02%	596
2025 Q4	$1.21M	Buy	5,689 +1,248	+28%	+$258K	0.01%	631
2025 Q3	$883K	Buy	+4,441	New	+$828K	0.01%	780
2024 Q4	–	Sell	-7,622	Closed	-$1.14M	–	1155
2024 Q3	$1.14M	Buy	7,622 +695	+10%	+$93.9K	0.01%	699
2024 Q2	$945K	Buy	6,927 +2,048	+42%	+$279K	0.01%	721
2024 Q1	$738K	Sell	4,879 -128	-3%	-$18.3K	0.01%	753
2023 Q4	$631K	Sell	5,007 -277	-5%	-$27.6K	0.01%	813
2023 Q3	$495K	Sell	5,284 -286	-5%	-$26.8K	0.01%	849
2023 Q2	$497K	Sell	5,570 -217	-4%	-$18.9K	0.01%	864
2023 Q1	$620K	Sell	5,787 -103	-2%	-$11.8K	0.01%	794
2022 Q4	$719K	Sell	5,890 -1,586	-21%	-$184K	0.01%	759
2022 Q3	$772K	Sell	7,476 -281	-4%	-$26.6K	0.01%	734
2022 Q2	$721K	Sell	7,757 -3,602	-32%	-$339K	0.01%	770
2022 Q1	$1.33M	Sell	11,359 -715	-6%	-$82.8K	0.02%	659
2021 Q4	$1.62M	Sell	12,074 -1,121	-8%	-$167K	0.02%	618
2021 Q3	$2.1M	Buy	13,195 +2,918	+28%	+$399K	0.03%	521
2021 Q2	$1.35M	Buy	10,277 +2,454	+31%	+$327K	0.02%	660
2021 Q1	$1.01M	Buy	7,823 +3,339	+74%	+$507K	0.02%	718
2020 Q4	$748K	Buy	4,484 +2,133	+91%	+$353K	0.01%	777
2020 Q3	$363K	Buy	2,351 +996	+74%	+$143K	0.01%	883
2020 Q2	$200K	Buy	1,355 +918	+210%	+$126K	﹤0.01%	1015
2020 Q1	$49K	Buy	+437	New	+$56.8K	﹤0.01%	1265

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Oppenheimer Asset Management's ASND Position: Q2 2026 in Review

Oppenheimer Asset Management reduced its Ascendis Pharma A/S (ASND) stake by 27% in Q2 2026, selling an estimated $467K and leaving 5,346 shares worth $1.43M. The position accounts for 0.01% of the portfolio, ranked #668.

Oppenheimer Asset Management first reported a position in ASND in Q1 2020 and has held it in 23 quarters since. The position peaked at $2.1M in Q3 2021. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Oppenheimer Asset Management held 5,346 shares of Ascendis Pharma A/S worth $1.43M as of Q2 2026.
Oppenheimer Asset Management sold 1,998 Ascendis Pharma A/S shares in Q2 2026, an estimated $467K.
Ascendis Pharma A/S made up 0.01% of Oppenheimer Asset Management's portfolio in Q2 2026, its #668 holding.
Oppenheimer Asset Management first reported a position in Ascendis Pharma A/S in Q1 2020 and has held it in 23 quarters since.
Oppenheimer Asset Management's Ascendis Pharma A/S position peaked at $2.1M in Q3 2021.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.